table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID 19 all comers
neutralizing antibody
cilgavimab and tixagevimab (Evusheld) Chen

1 studies excluded by filtering options 2

5570 CT-P59 1.2, 2020 210excludedrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons